Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02599532 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Apixaban in Nephrotic Syndrome
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02599532 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 21 participants.
The verdict
NCT02599532, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is to investigate the pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome.
Interventions
- DRUG apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-04-30 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02599532
The ClinicalTrials.gov registry entry for NCT02599532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apixaban is the first listed.
NCT02599532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02599532 about?
NCT02599532 is a clinical study titled "Pharmacokinetics of Apixaban in Nephrotic Syndrome". This study is to investigate the pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome.
What is the current status of trial NCT02599532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-04-30. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02599532?
The interventions under investigation include: apixaban (DRUG).
Who is sponsoring clinical trial NCT02599532?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.